These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19458483)

  • 1. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
    Chen J; Xie F; Chen K; Wang D; Jiang H; Li J; Pan F; Chen S; Zhang Y; Ruan Z; Huang H; Zou L; Liang H
    Cancer Biol Ther; 2009 Jul; 8(14):1424-30. PubMed ID: 19458483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy.
    Chen J; Luo X; Xie G; Chen K; Jiang H; Pan F; Li J; Ruan Z; Pang X; Liang H
    Medicine (Baltimore); 2016 May; 95(19):e3652. PubMed ID: 27175691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
    Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
    Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array.
    Kweekel DM; Antonini NF; Nortier JW; Punt CJ; Gelderblom H; Guchelaar HJ
    Br J Cancer; 2009 Jul; 101(2):357-62. PubMed ID: 19536092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between the Asp1104His polymorphism of the nucleotide excision repair gene ERCC5 and treatment sensitivity to oxaliplatin in patients with advanced colorectal cancer in China.
    Kong J; Liu Z; Cai F; Xu X; LiuI J
    Clinics (Sao Paulo); 2018 Dec; 73():e455. PubMed ID: 30517302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
    Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ
    Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter polymorphisms in DNA repair gene ERCC5 and susceptibility to gastric cancer in Chinese.
    Duan Z; He C; Gong Y; Li P; Xu Q; Sun LP; Wang Z; Xing C; Yuan Y
    Gene; 2012 Dec; 511(2):274-9. PubMed ID: 22982416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.
    He C; Duan Z; Li P; Xu Q; Yuan Y
    Anticancer Drugs; 2013 Mar; 24(3):300-5. PubMed ID: 23211354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy.
    Liu D; Wu HZ; Zhang YN; Kang H; Sun MJ; Wang EH; Yang XL; Lian MQ; Yu ZJ; Zhao L; Olopade OI; Wei MJ
    Mol Carcinog; 2012 Oct; 51 Suppl 1():E83-93. PubMed ID: 22213216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
    Viguier J; Boige V; Miquel C; Pocard M; Giraudeau B; Sabourin JC; Ducreux M; Sarasin A; Praz F
    Clin Cancer Res; 2005 Sep; 11(17):6212-7. PubMed ID: 16144923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive impact of genetic polymorphisms in DNA repair genes on susceptibility and therapeutic outcomes to colorectal cancer patients.
    Sun K; Gong A; Liang P
    Tumour Biol; 2015 Mar; 36(3):1549-59. PubMed ID: 25355595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer.
    Zhang W; Stoehlmacher J; Park DJ; Yang D; Borchard E; Gil J; Tsao-Wei DD; Yun J; Gordon M; Press OA; Rhodes K; Groshen S; Lenz HJ
    Clin Colorectal Cancer; 2005 Jul; 5(2):124-31. PubMed ID: 16098254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of ABCB-1, ERCC-1 and ERCC-2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India.
    Varma A; Mathaiyan J; Shewade D; Dubashi B; Sunitha K
    J Clin Pharm Ther; 2020 Aug; 45(4):617-627. PubMed ID: 32399998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
    Liang J; Li QF; Yao RY; Lü HY; Jiang J; Sun YY; Song SA; Jiang T
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):515-9. PubMed ID: 21029695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population.
    Dai Q; Luo H; Li XP; Huang J; Zhou TJ; Yang ZH
    Mutagenesis; 2015 May; 30(3):441-9. PubMed ID: 25690281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of ERCC5 polymorphisms in non‑small cell lung cancer risk and responsiveness/toxicity to cisplatin‑based chemotherapy in the Chinese population.
    Li M; Chen R; Ji B; Fan C; Wang G; Yue C; Jin G
    Oncol Rep; 2021 Mar; 45(3):1295-1305. PubMed ID: 33469680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer.
    Lv H; Li Q; Qiu W; Xiang J; Wei H; Liang H; Sui A; Liang J
    Pathol Oncol Res; 2012 Oct; 18(4):1009-14. PubMed ID: 22549274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
    Ruzzo A; Graziano F; Loupakis F; Rulli E; Canestrari E; Santini D; Catalano V; Ficarelli R; Maltese P; Bisonni R; Masi G; Schiavon G; Giordani P; Giustini L; Falcone A; Tonini G; Silva R; Mattioli R; Floriani I; Magnani M
    J Clin Oncol; 2007 Apr; 25(10):1247-54. PubMed ID: 17401013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
    Park JH; Kim NS; Park JY; Chae YS; Kim JG; Sohn SK; Moon JH; Kang BW; Ryoo HM; Bae SH; Choi GS; Jun SH
    J Cancer Res Clin Oncol; 2010 Aug; 136(8):1135-42. PubMed ID: 20091185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.